| |
bb Lapatinib + Capecitabine
|
|---|
|
Characteristic
|
Brain metastasis (n = 58)
|
No Brain metastasis (n = 128)
|
Pvaluea
|
No Prior capecitabine (n = 95)
|
Prior capecitabine (n = 91)
|
Pvaluea
|
Total (n = 186†)
|
|---|
| |
No.
|
%
|
No.
|
%
| |
No.
|
%
|
No.
|
%
| |
No.
|
%
|
|---|
|
Median age, yrs (range)
|
46.5
|
(27-70)
|
49
|
(27-71)
|
0.170
|
48
|
(27-71)
|
47
|
(29-70)
|
0.960
|
48
|
(27-71)
|
|
<50
|
38
|
(65.5)
|
67
|
(52.3)
|
0.1111
|
53
|
(55.8)
|
52
|
(57.1)
|
0.8832
|
105
|
(56.2)
|
|
≥50
|
20
|
(34.5)
|
61
|
(47.7)
| |
42
|
(44.2)
|
39
|
(42.9)
| |
82
|
(43.9)
|
|
Hormone receptor
|
|
ER + and/or PR+
|
28
|
(49.1)
|
45
|
(35.4)
|
0.103
|
36
|
(38.3)
|
37
|
(41.1)
|
0.764
|
73
|
(39.7)
|
|
ER- and PR-
|
29
|
(50.9)
|
82
|
(64.6)
| |
58
|
(61.7)
|
53
|
(58.9)
| |
111
|
(60.3)
|
|
Unknown
|
1
|
(1.7)
|
1
|
(0.8)
| |
1
|
(1.0)
|
1
|
(1.1)
| |
2
|
(1.1)
|
|
No. metastatic sites
|
|
1
|
5
|
(8.9)
|
17
|
(13.6)
|
0.174
|
14
|
(15.2)
|
8
|
(9.0)
|
0.042
|
22
|
(12.2)
|
|
2
|
15
|
(26.8)
|
47
|
(37.6)
| |
37
|
(40.2)
|
25
|
(28.1)
| |
62
|
(34.3)
|
|
≥ 3
|
36
|
(64.3)
|
61
|
(48.8)
| |
41
|
(44.6)
|
56
|
(62.9)
| |
97
|
(53.6)
|
|
Unknown
|
2
|
(3.4)
|
3
|
(2.3)
| |
3
|
(3.2)
|
2
|
(2.2)
| |
5
|
(2.7)
|
|
Pattern of metastasis
|
|
Visceral only
|
18
|
(31.6)
|
56
|
(45.5)
|
0.161
|
34
|
(37.8)
|
40
|
(44.4)
|
0.617
|
74
|
(41.1)
|
|
Non-visceral only
|
8
|
(14.0)
|
11
|
(8.9)
| |
11
|
(12.2)
|
8
|
(8.9)
| |
19
|
(10.6)
|
|
Both
|
31
|
(54.4)
|
56
|
(45.5)
| |
45
|
(50.0)
|
42
|
(46.7)
| |
87
|
(48.3)
|
|
Unknown
|
1
|
(1.7)
|
5
|
(3.9)
| |
5
|
(5.3)
|
1
|
(1.1)
| |
6
|
(3.2)
|
|
Prior capecitabine
b
|
30
|
(51.7)
|
61
|
(47.7)
| |
0
|
(0.0)
|
91
|
(48.9)
| |
91
|
(48.9)
|
|
> 3 Prior chemotherapy regimens
|
22
|
(37.9)
|
45
|
(35.2)
| |
10
|
(10.5)
|
57
|
(62.6)
| |
67
|
(36.0)
|
|
Median duration of trastuzumab, wks (range)
|
35.4
|
(4.0-113.6)
|
20.6
|
(0.1-105.0)
|
0.016
|
27.3
|
(0.1-104.4)
|
21.6
|
(3.0-113.6)
|
0.252
|
24.1
|
(0.1-113.6)
|
|
Interval from last dose of trastuzumab prior to study entry, wks
|
|
Median (range)
|
11.6
|
(2.7-146.6)
|
20.9
|
(0.1-172.3)
|
0.365
|
7.7
|
(0.1-172.3)
|
24.9
|
(1.4-160.9)
|
0.001
|
14.6
|
(0.1-172.3)
|
|
< 4
|
3
|
(5.2)
|
16
|
(12.6)
|
0.341
|
14
|
(14.7)
|
5
|
(5.6)
|
<0.001
|
19
|
(10.3)
|
|
4 - 8
|
17
|
(29.3)
|
33
|
(26.0)
| |
37
|
(39.0)
|
13
|
(14.4)
| |
50
|
(27.0)
|
|
>8
|
38
|
(65.5)
|
78
|
(61.4)
| |
44
|
(46.3)
|
72
|
(80.0)
| |
116
|
(62.7)
|
|
Unknown
|
0
|
(0.0)
|
1
|
(0.8)
| |
0
|
(0.0)
|
1
|
(1.1)
| |
1
|
(0.5)
|
-
a Fisher’s exact χ2 test for categorical variables and independent t-test for continuous variables; two-sided p-values.
-
b Included 8 cases who had lapatinib during capecitabine.
-
† Because of few information (only age and study date), 1 patient was excluded.
- ‘Unknown’ included missing values.
